S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)

Natera (NTRA) Stock Price, News & Analysis

$91.12
+0.66 (+0.73%)
(As of 01:51 PM ET)
Today's Range
$89.20
$92.42
50-Day Range
$64.62
$92.90
52-Week Range
$36.90
$96.24
Volume
437,581 shs
Average Volume
1.52 million shs
Market Capitalization
$11.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.36

Natera MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
14.4% Downside
$78.36 Price Target
Short Interest
Healthy
6.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.08mentions of Natera in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$26.21 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.43) to ($1.01) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.83 out of 5 stars

Medical Sector

590th out of 939 stocks

Medical Laboratories Industry

14th out of 20 stocks

NTRA stock logo

About Natera Stock (NASDAQ:NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

NTRA Stock Price History

NTRA Stock News Headlines

AI Bubble Now at Critical Mass
Washington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.
Natera (NASDAQ:NTRA) Hits New 52-Week High at $96.24
AI Bubble Now at Critical Mass
Washington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.
NTRA Apr 2024 90.000 put
NTRA Apr 2024 87.500 call
NTRA Apr 2024 80.000 put
NTRA Mar 2024 82.500 call
NTRA Oct 2024 97.500 call
Natera Full Year 2023 Earnings: Beats Expectations
Decoding Natera Inc (NTRA): A Strategic SWOT Insight
Natera to Participate in March Investor Conferences
See More Headlines
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:NTRA
Fax
N/A
Employees
3,293
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$78.36
High Stock Price Target
$110.00
Low Stock Price Target
$48.00
Potential Upside/Downside
-13.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

Net Income
$-434,800,000.00
Pretax Margin
-40.14%

Debt

Sales & Book Value

Annual Sales
$1.08 billion
Book Value
$6.37 per share

Miscellaneous

Free Float
109,383,000
Market Cap
$10.92 billion
Optionable
Optionable
Beta
1.39
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

NTRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Natera stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NTRA shares.
View NTRA analyst ratings
or view top-rated stocks.

What is Natera's stock price target for 2024?

13 analysts have issued twelve-month price targets for Natera's shares. Their NTRA share price targets range from $48.00 to $110.00. On average, they anticipate the company's share price to reach $78.36 in the next twelve months. This suggests that the stock has a possible downside of 14.4%.
View analysts price targets for NTRA
or view top-rated stocks among Wall Street analysts.

How have NTRA shares performed in 2024?

Natera's stock was trading at $62.64 at the start of the year. Since then, NTRA shares have increased by 46.2% and is now trading at $91.57.
View the best growth stocks for 2024 here
.

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our NTRA earnings forecast
.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) issued its quarterly earnings results on Wednesday, February, 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.09. The medical research company had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative net margin of 40.16% and a negative trailing twelve-month return on equity of 62.19%.

What guidance has Natera issued on next quarter's earnings?

Natera updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?
When did Natera IPO?

Natera (NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Who are Natera's major shareholders?

Natera's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.13%), Vanguard Group Inc. (9.09%), RTW Investments LP (2.16%), Kynam Capital Management LP (2.00%), Principal Financial Group Inc. (1.42%) and Norges Bank (1.12%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, John Fesko, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends
.

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NTRA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners